Investor Presentaiton

Appendix B CSL Vifor & CSL Seqirus - Key Products HY24 Revenue By Therapy Group $m 0% Other Income $14 5%, Pandemic, $85 4%, In License, $65 CSL SEQIRUS Fluad Therapy Group Sales $m Change1% Adjuvanted 988 14% 7%, Egg Based, $123 Flucelvax Afluria Cell culture 529 (13%) Egg-based 123 9% 55%, Adjuvanted, $988 CSL VIFOR Therapy Group Sales $m Ferinject/Injectafer Iron 376 9%, Non Dialysis, 2%, Other, $17 $90 Mircera Venofer Dialysis 313 Iron 82 Veltassa Velphoro Maltofer Non Dialysis 66 Dialysis 46 39%, Dialysis, $399 Iron 46 1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail. 24 Driven by Our Promise 29%, Cell Culture, $529 50%, Iron, $505 CSL

View entire presentation